Erlotinib Tab 150mg

Description

Erlotinib Tablet

• Product Overview
Erlotinib Tablet is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of certain types of non-small cell lung cancer (NSCLC) and other EGFR-related cancers. It works by blocking EGFR signaling pathways involved in cancer cell growth and multiplication, helping to slow or stop tumor progression. Erlotinib is used under the supervision of an oncology specialist.

• Available Strength
– Erlotinib 150 mg Tablet

• Therapeutic Category
Anticancer Agent / EGFR Tyrosine Kinase Inhibitor (TKI)

• Indications
Erlotinib Tablet is indicated for:
– EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
– Locally Advanced or Metastatic NSCLC
– Pancreatic Cancer (in combination therapy as prescribed)
– Other approved EGFR-related cancer indications

• Common Side Effects
Some patients may experience:
– Skin rash
– Diarrhea
– Loss of appetite
– Nausea
– Fatigue
– Dry skin

• Serious Side Effects
Seek immediate medical attention if any of the following occur:
– Interstitial lung disease (breathing difficulty, cough, fever)
– Severe liver toxicity
– Severe skin reactions
– Gastrointestinal perforation (rare)
– Eye disorders

• Precautions
– Use only under oncologist supervision.
– EGFR mutation testing may be required before use in lung cancer.
– Regular monitoring of liver function may be required.
– Inform healthcare providers about other medicines being taken.
– Use cautiously in patients with lung disease, liver impairment, or eye disorders.
– Store below 25°C, protected from moisture and direct sunlight.

• Technical Information

• Active Ingredient
– Erlotinib Hydrochloride equivalent to 150 mg Erlotinib

• Mechanism of Action
Erlotinib selectively inhibits the EGFR tyrosine kinase enzyme, blocking signaling pathways responsible for cancer cell growth, proliferation, and survival.

• Dosage Form
Film-Coated Tablet

• Route of Administration
Oral

• Shelf Life
24–36 Months (depending on packaging and regulatory requirements)

• Storage Conditions
Store below 25°C in a dry place, protected from moisture.

• Product Specifications
Product Name:- Erlotinib Tablet
Generic Name:- Erlotinib Hydrochloride
Strength:- 150 mg
Dosage Form:- Film-Coated Tablet
Category:- Oncology / EGFR Tyrosine Kinase Inhibitor
Packaging:- Blister Packing / Customized Export Packing
Pack Size:- As per requirement
Shelf Life:- 24–36 Months
Storage:- Below 25°C
Origin:- India

• Regulatory Status & Supply Information
– Manufactured in WHO-GMP compliant facilities.
– Available for international oncology markets (subject to importing country regulations).
– Export documentation support available.
– Private Label Manufacturing available where permitted.
– Third-Party Manufacturing available.
– Customized export packaging available.
– Bulk supply available for distributors, oncology centers, hospitals, and government healthcare programs.

• Who Should Source This Product?
This product is ideal for:
– Pharmaceutical Importers
– Oncology Product Distributors
– Hospital Procurement Companies
– Cancer Treatment Centers
– Government Healthcare Programs
– Tender Suppliers
– Specialty Medicine Suppliers
– Private Label Brands

• Why Source From Mediora Exports?
– Trusted Pharmaceutical Exporter from India
– WHO-GMP Manufacturing Partners
– Competitive International Pricing
– Wide Oncology Product Portfolio
– Reliable Global Supply Chain
– Flexible Packaging Options
– Complete Export Documentation Support

• Contact Details
Mediora Exports

📧 Email: info@medioraexports.com
📱 Phone/WhatsApp: +91 99047 64844